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Abstract
Background: Duchenne muscular dystrophy (DMD) is an inherited and progressive disease causing striated muscle
deterioration. Patients in their twenties generally die from either respiratory or cardiac failure. In order to improve
the lifespan and quality of life of DMD patients, it is important to prevent or reverse the progressive loss of
contractile function of the heart. Recent studies by our labs have shown that the peptide NBD (Nemo Binding
Domain), targeted at blunting Nuclear Factor B (NF-B) signaling, reduces inflammation, enhances myofiber
regeneration, and improves contractile deficits in the diaphragm in dystrophin-deficient mdx mice.
Methods: To assess whether cardiac function in addition to diaphragm function can be improved, we investigated
physiological and histological parameters of cardiac muscle in mice deficient for both dystrophin and its homolog
utrophin (double knockout = dko) mice treated with NBD peptide. These dko mice show classic pathophysiological
hallmarks of heart failure, including myocyte degeneration, an impaired force-frequency response and a severely
blunted b-adrenergic response. Cardiac contractile function at baseline and frequencies and pre-loads throughout
the in vivo range as well as b-adrenergic reserve was measured in isolated cardiac muscle preparations. In addition,
we studied histopathological and inflammatory markers in these mice.
Results: At baseline conditions, active force development in cardiac muscles from NBD treated dko mice was more
than double that of vehicle-treated dko mice. NBD treatment also significantly improved frequency-dependent
behavior of the muscles. The increase in force in NBD-treated dko muscles to b-adrenergic stimulation was robustly
restored compared to vehicle-treated mice. However, histological features, including collagen content and
inflammatory markers were not significantly different between NBD-treated and vehicle-treated dko mice.
Conclusions: We conclude that NBD can significantly improve cardiac contractile dysfunction in the dko mouse
model of DMD and may thus provide a novel therapeutic treatment for heart failure.
Background
Duchenne muscular dystrophy (DMD) is a degenerating
striated muscle disease caused by the absence of the
dystrophin protein[1]. Although limb muscle weakness
and the loss of ambulation are usually the initial clinical
signs of the disease, patients with DMD die from
respiratory failure or heart failure. Pertaining to the
heart, ninety-five percent of DMD patients develop
dilated cardiomyopathy, and over twenty-five percent
die from heart failure [2]. These numbers are predicted
to grow as prophylactic treatments targeted at maintain-
ing respiratory function improve[3]. This prediction is
further supported by the majority of patients with
Becker muscular dystrophy (BMD), who have dystrophin
mutations that cause a milder skeletal muscle disease,
and typically progress to heart failure[3].
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tral focus of therapeutic development for DMD and
BMD. However, therapies targeting only skeletal muscle
but not cardiac muscle could potentially aggravate the
already present cardiac dysfunction[4]. In order to
improve lifespan and quality of life, progressive loss of
contractile function in the heart also needs to be pre-
vented or halted. Our recent studies have shown that
the inhibition of the NF-B signaling pathway can
improve both limb and diaphragm muscle contractile
function in the dystrophin-deficient mdx genotypic
mouse model of DMD[5,6]. This inhibition was achieved
by a small, 11 amino-acid peptide named NBD (NEMO
Binding Domain) that binds preferentially to the C-
terminal regions of the IKKa and IKKb catalytic compo-
nents of IB kinase (IKK) preventing association with
the NF-B essential modulator (NEMO) regulatory sub-
unit and prohibiting downstream NF-B signaling. The
NBD peptide blunted NF-B signaling, reduced inflam-
mation, enhanced myofiber regeneration, and improved
contractile function in the diaphragm muscle in mdx
mice[5,6].
It is interesting to note that of the pharmacological
inhibitors tested for improvement of skeletal muscles in
animal models of DMD, none, to our knowledge, were
directly tested for their effects to improve cardiac func-
tion. Recent studies even suggest that the current stan-
dard of care pharmacological treatment for DMD, the
corticosteroid prednisone, worsens cardiac function in
the mdx model[7,8]. It is not known whether cardiac
contractile function can be improved by NBD treatment,
but given its ability to dampen both the inflammatory
response and stimulate news k e l e t a lm u s c l eg r o w t h
resulting in improved contractile function, testing the
potential of NBD to improve cardiac function in a
DMD-related model of cardiomyopathy is warranted. To
this end, we focused our current investigation on trans-
lating the basic finding of effective NF-B inhibition
into improved cardiac contractile function. We used a
model of DMD that is known to have a more severe
cardiac dysfunction than the mdx mouse. In this double
knock-out (dko) mouse, where both dystrophin and its
partially compensating homolog utrophin are both
absent[9], we previously showed that cardiac contractile
function at 8 weeks-of-age[10] is severely affected.
These relatively young dko mice[10] display the classic
pathophysiological hallmarks of end-stage human car-
diac failure with a reduced contractile ability, a negative
force-frequency relationship[11], and a severely blunted
b-adrenergic response[12]. In addition these dko mice
show cardiac muscle degeneration and by 10 weeks of
age they have replacement of damaged cardiomyocytes
with fibrotic scars[13], similar to both DMD patients
[14] and the larger heart failure population[15,16].
Therefore, improvement in cardiac function in these
mice would have possible therapeutic implications not
only for cardiomyopathy in the muscular dystrophies,
but also possibly for the much larger population of
heart failure patients suffering from cardiac contractile
dysfunction.
In this study, to completely assess functional aspects
of NBD treatment, we investigated both the baseline
contractile function of the myocardium and the regula-
tion of contractility in the dko mice. We assessed
length-dependent activation, frequency-dependent acti-
vation, and b-adrenergic stimulation in isolated dko car-
diac papillary muscles treated with NBD peptide or
vehicle. The results indicate that NBD can significantly
improve cardiac contractile dysfunction in this model of
muscular dystrophy cardiomyopathy.
Methods
Mice
Utrophin/dystrophin-deficient double knockout (utrn
-/-;
mdx, dko) offspring were born at an approximately 1:4
ratio from matings between utrn
+/-;mdx mice. Offspring
were genotyped shortly after birth as described pre-
viously[9] and both male and female dko mice were
used for treatment and control groups. Experimental
protocols involving mice were approved by the Institu-
tional Animal Care and Use Committee at The Ohio
State University.
Peptide synthesis
Peptide synthesis of NBD was the same as described
previously[5].
Treatment regimen
Treatment with NBD was initiated when mice were less
than one week of age. NBD diluted in 10% DMSO in
phosphate buffered saline (PBS) was delivered by intra-
peritoneal injection 3 times weekly until the mice were
8 weeks-of-age. Because mice were actively growing dur-
ing the first half of the treatment time and as adults
their weights are variable, dko mice were weighed prior
to each injection until 4 weeks of age and then once
each week thereafter to achieve the desired 10 mg/kg
peptide dosage. In previous studies scrambled peptide
sequences showed no functional differences versus vehi-
cle alone[5,17]. The control group for this study con-
s i s t e do fd k om i c et h a tw e r ei n j e c t e do nt h es a m e
schedule with an equal volume of the vehicle (10%
DMSO in PBS).
EMSA and Western Blotting
EMSA and western analyses were performed as pre-
viously described for skeletal muscle tissue [5,6,18] from
cardiac ventricular tissue from vehicle or NBD treated
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mic extracts were prepared using an extraction buffer
with standard protease inhibitors. After incubation and
mild centrifugation, nuclear extracts were further iso-
lated by using two pellet volumes of extraction buffer
and standard protease inhibitors. Nuclear pellets were
resuspended by vortexing and transferred to fresh tubes
for use in EMSA analysis. These prepared nuclear
extracts were either incubated with a radioactive oligo-
nucleotide containing a consensus NF-B binding site
and fractionated on a 5% non-denaturing polyacrylamide
gel (EMSA) or used in a western blot and probed
against p65.
Assessment of contractile physiology
At the end of the treatment regimen, contractile func-
tion of cardiac muscle tissue was assessed in vitro,a s
previously described[10,19,20]. Briefly, under deep
anesthesia, hearts were rapidly removed, and flushed
with a Krebs-Henseleit solution. The right ventricle was
opened, and small papillary muscles were dissected
under a stereo microscope. The muscles were mounted
in an experimental chamber, superfused with Krebs-
Henseleit solution, containing 1.5 mM Ca
2+,a t3 7 ° C .
Muscles were electrically stimulated to twitch contract,
and force of contraction was recorded. First, after the
muscle had equilibrated in the set-up, muscle length
was increased until a further increase in length no
longer resulted in an increase in active twitch developed
peak force. This length was then considered optimal
length. Because the heart regulates contractile force
through several physiological mechanisms, it is impor-
tant not only to assess baseline contractile parameters,
but also the response to normal physiological regulatory
mechanisms. Therefore, we assessed the main three
mechanisms used by the heart to regulate contractile
strength: length-dependent behavior, frequency-depen-
dent stimulation, and b-adrenergic stimulation. After
assessment of baseline contractile parameters, at a sti-
mulation frequency of 4 Hz, these three regulatory
responses were assessed in each muscle, using protocols
described previously[10,19]. The experimenters were
blinded to the treatment of the mice. If more than 1
muscle was measured per mouse, data were averaged to
reduce variability. N-numbers reported reflect numbers
of mice studied.
Histology
After cardiac muscle samples for physiological analyses
were removed, the remaining heart tissue was frozen in
Optimal Cutting Temperature (O.C.T.) medium (Tissue-
Tek, Torrance, CA) on liquid nitrogen-cooled isopen-
tane. Serial cryosections (8 μm) were cut from the tissue
blocks and used for the following staining procedures.
For viewing of gross histology, sections were fixed in
100% ethanol and then stained with hematoxylin and
eosin using standard procedures. For specific detection
of fibrosis, fibroblasts, and immune cells in regions of
cardiac damage, immunofluorescence was performed on
serial cryosections. Unfixed cryosections were equili-
brated in KPBS (16.4 mM K2HPO4,3 . 6m MK H 2PO4,
160 mM NaCl) for 5 minutes then blocked with KPBS +
1% gelatin for 15 minutes. Slides were washed with
KPBS + 0.2% gelatin (KPBSG), then incubated for two
hours with primary antibodies, which were diluted in
KPBSG + 1% normal goat serum, against collagen I
(Abcam, Cambridge, MA, ab292 rabbit polyclonal) at
1:200, ER-TR7 (Abcam ab51824 rat monoclonal) at
1:100, or CD45 (BD Pharmingen, Franklin Lakes, NJ,
550539 rat monoclonal) at 1:50. Slides were washed and
then incubated for one hour with Cy3-conjugated goat
secondary antibodies against rabbit IgG (Jackson
Immuno Research, West Grove, PA,111-165-144) or rat
IgG (Jackson Immuno Research 712-165-153), diluted
1:100 in KPBSG + 1% normal goat serum, for detection
of bound primary antibodies. Slides were again washed,
and then mounted in Vectashield (Vector Labs, Burlin-
game, CA) containing 2 μg/ml DAPI (Sigma, Saint
Louis, MO) to stain nuclei. Fluorescence was viewed
with a Nikon Eclipse 800 microscope (Nikon Corpora-
tion, Tokyo, Japan) and imaged with a SPOT-RTslider
digital camera and SPOT software (Diagnostic Instru-
ments, Inc., Sterling Heights, MI). Control experiments
using secondary antibodies only revealed no staining.
Statistics
Contractile forces were analyzed using unpaired t-tests
or ANOVA, followed by post-hoc tests where applicable.
A two-tailed P value of < 0.05 was considered
significant.
Results
At 8 weeks-of-age after treatments three times per week
(starting in the first week of life) with NBD peptide
( N B D )o ra ne q u i v a l e n tv o l u m eo fv e h i c l e ,f u n c t i o n a l
and histological parameters of dko hearts were assessed.
Contractile strength of isolated multicellular cardiac
muscles was first examined. These linear muscle pre-
parations contain cardiomyocytes, fibroblasts, and
endothelial cells, and are arranged in a linear fashion
facilitating both qualitative and quantitative assessment
of mechanical function and its regulatory process[21,22].
At baseline conditions (optimal length, 4 Hz stimulation
frequency, 37°C), active force development in muscles
f r o mN B Dt r e a t e dd k om i c ew a ss i g n i f i c a n t l yh i g h e r
than in muscle from vehicle treated dko mice (12.5 ±
1.8 vs. 5.2 ± 1.8 mN/mm
2, P < 0.05, Figure 1A). Quanti-
tatively, this difference is similar to that observed
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our previous study[10], indicating a full recovery of
active developed force by NBD. The diastolic tension
needed to reach optimal active tension was not signifi-
cantly different between the two groups, and was 11.7 ±
1.9 mN/mm
2 in the vehicle group, and 10.8 ± 1.9 mN/
mm
2 in the NBD treated group (P = 0.75). The maximal
speed of contraction and relaxation (dF/dtmax and dF/
dtmin respectively) was also significantly higher in mus-
cles from NBD treated mice (P < 0.05, Figure 1B). How-
ever, the increase in the derivative of force is mainly a
result from the overall increase in force. When we
assessed the time from stimulation to peak tension, and
the time from peak tension to 90% relaxation, we only
observed a small, non-significant acceleration of con-
tractile kinetics (Figure 1C). This too indicates an
improvement in function, as often increase force devel-
opment per se leads to a slowing of the relaxation[23],
possibly impairing diastolic function. Clearly, despite the
increased force in muscles from NBD treated mice,
these relaxation kinetics were not slower, and even
trended to be faster.
In order to assess whether force development was
increased independent of its regulatory mechanisms, we
next investigated whether the normal physiological regu-
latory mechanisms that augment cardiac contractility
were altered by NBD treatment. Normal physiological
regulation of contractile function occurs via several
mechanisms, and is used to increase blood flow when
bodily demand is higher, such as occurs when exercis-
ing. The most well known of these regulatory mechan-
isms is the Frank-Starling mechanism, which results in
an increase in contractile strength when preload (ventri-
cular volume at start of contraction) of the ventricle, or
length of the cardiac muscle cells, is increased. To
mimic this mechanism in our in vitro preparation, we
assessed contractile strength at 4 different muscle
lengths (representing different loading conditions of the
ventricle), ranging from 85% of optimal length, which is
near-slack length of the muscle, to optimal length. We
observed that length-dependent activation per se (shape
of the curve) was not different in muscles from NBD
treated compared to vehicle treated dko mice (Figure 2).
Therefore, as length of the muscle increased, force of
contraction increased in both groups. Statistical analysis
via ANOVA indicated that the treatment difference on
force was significant, as was the effect of length, but not
the interaction between these two, indicating length-
dependent behavior is unchanged after NBD treatment.
Next, we investigated the effect of NBD treatment on
a second mechanism of cardiac contractile regulation:
frequency-dependent behavior. From baseline conditions
at optimal length, stimulation frequency was increased
from 4 to 6, 8, 10, 12 and 14 Hz, encompassing the in
vivo r a n g ef o rt h em o u s e [ 2 4 ] .A sw eh a v ep r e v i o u s l y
shown in untreated dko mice[10], vehicle treated dko
mice show a pathological negative force-frequency with
an increase in stimulation rate leading to a decrease in
peak contractile force. ANOVA indicated not only that
both frequency and treatment were significant, but also
that the interaction was significantly different between
NBD and vehicle treated dko mice. Due to the spread in
the absolute forces, this cannot be easily illustrated from
the absolute force values (Figure 3A) but when each
muscle is normalized to its own initial force level at 4
Hz, this relationship is more easily represented (Figure
3B). In vehicle treated mice a shift from 4 to 10 Hz sti-
mulation frequency resulted in a 46 ± 6% loss of force
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Figure 1 Baseline contractile function. A. Muscles from NBD treated dko mice (n = 9 muscles from n = 7 mice) exhibited a higher active
developed force under baseline conditions (1.5 mM Ca
2+, 4 Hz, 37°C) compared to muscles from vehicle treated control dko mice (n = 5
muscles from n = 4 mice). B. Maximum and minimum derivative of force (dF/dt) was higher in NBD treated mice. C. Time from stimulation to
peak tension and time from peak tension to 90% relaxation were slightly, but not significantly, slower in non-treated muscles. * indicates a
difference of P < 0.05 between the two groups.
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NBD-treated mice the change in force from 4 to 10 Hz
stimulation frequency was not significant. This flat
force-frequency relationship is again nearly identical in
quality and quantity compared to results obtained in
healthy WT mice[10]. Thus, NBD treatment signifi-
cantly prevented a worsening of frequency-dependent
behavior of the muscles. When stimulation rate
increased, both groups responded with a virtually equal
increase in the rate of kinetics. The average acceleration
of the 50% relaxation time was 10.2 ms in NBD treated
mice versus 9.8 ms in vehicle treated dko mice (not
shown, difference not significant).
The third major mechanism that regulates contractile
function in vivo is b-adrenergic stimulation. In order to
assess this response, we exposed the twitch contracting
muscles to increasing concentrations of the b-adrenergic
agonist isoproterenol. As shown in Figure 4, the
response in vehicle treated dko muscles to isoproterenol
is pathologically weak, with an average increase in force
of only 2.8 mN/mm
2. This weak response is in close
agreement with our previously published findings[10]. In
sharp contrast, the response in NBD treated dko mice is
robust, more than triple (average of 10.0 mN/mm
2) than
the response observed in vehicle treated mice. Again,
this restored response was similar in magnitude to that
of healthy wild-type mice in our previous study[10]. The
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Figure 2 Length-dependent activation.W h e nt h em u s c l ew a s
stretched from 85% of optimal length (near slack, virtually no
passive tension, 37°C) to optimal length, active force development
significantly increased in both NBD treated and vehicle treated
groups. Repeated measures ANOVA indicated that impact of both
factors, treatment and length, were significant (P < 0.05), but not
the interaction, indicating unchanged length-dependent behavior
after NBD treatment in dko mice. * indicates a difference of P <
0.05 between the two groups.
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and not significantly different (not shown).
Next, we examined the pharmacodynamic efficacy of
the NBD peptide in cardiac muscles of dko treated
mice. Both NF-B DNA binding activity, as well as
nuclear levels of the p65 subunit of NF-Bw e r ee l e -
vated in the dko heart. In general, this activation was
effectively reduced in NBD treated dko mice (Figure 5).
These results were consistent with our previous findings
in diaphragm muscles from NBD treated mdx mice[5,6],
together supporting that NBD improvement of cardiac
contractile dysfunction in dko mice occurs through the
inhibition of the NF-B signaling pathway.
Lastly, we investigated whether NBD treatment of dko
mice resulted in an improvement in cardiac histopatho-
logical features of this model. Between eight and ten
weeks-of-age, dko mice display myocardial damage fol-
lowed by fibrotic scarring in damaged regions[13].
Despite the robust improvement in contractile function
resulting from NBD-treatment, and the well-documen-
ted role of NF-B in inflammation, histopathological
features of the dko myocardium were not markedly
improved by NBD treatment.
We observed large fibrotic scars (Figure 6A) in the
hearts of most of dko mice in this study regardless of
treatment (5 of 7 [71%] NBD treated mice, versus 3 of 4
[75%] vehicle treated mice). Of note, the eight week-old
vehicle and NBD treated dko mice in this study that
were handled for injections three times per week,
showed more advanced cardiac damage than other dko
mice analyzed at eight weeks-of-age over the past dec-
ade that underwent minimal handling (data not shown).
The amount of damage in both groups of dko mice in
this study was more consistent with the damage present
in ten week-old dko mice [13]. Immunofluorescence
using collagen I antibodies showed that the fibrotic
regions were highly collagenous in both groups (Figure
6B). Fibroblasts, known to be responsible for much of
the cardiac remodeling in cardiomyopathy via secretion
of matrix metalloproteinases and collagen[15], are pre-
sent in large numbers in both NBD and vehicle treated
dko hearts in regions of fibrosis (Figure 6C). Immune
cell infiltrates are likely required for clearing damaged
myocardial tissue, but at the time-point analyzed here,
w ec o u l dn o td e t e c tt h ep r e s e n c eo fm o r et h a nav e r y
few sporadic hematopoietic-lineage cells in damaged
regions of hearts from either NBD or vehicle treatment
groups using antibodies that recognize the general
hematopoietic markers CD-45 (Figure 6D) or CD-11b
or the more specific macrophage marker F4/80 (data
not shown). Intermediate timepoints to quantifiably
assess the inflammatory response were beyond the
scope of this end-point driven study.
Discussion
Cardiac contractile dysfunction is one of the leading
causes of death in DMD. Clinical treatment of this
debilitating aspect of DMD is paramount in extending
Figure 5 NBD is effective in inhibiting NF-B in cardiac
muscles from dko mice. Nuclear extracts were prepared from
hearts of vehicle (n = 4) or NBD (n = 7) treated dko mice and
analyzed by either EMSA (upper panel) or western blot probing for
nuclear fraction p65 (bottom panels). Nonspecific band (NS) is
shown on the western blot to demonstrate equivalent protein
loading.
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Figure 4 b-adrenergic response. The severely blunted response to
the b-adrenergic agonist isoproterenol in muscles from dko mice is
significantly ameliorated by NBD treatment. ANOVA (repeated
measures) indicated that both the factors isoproterenol and
frequency, as well as the interaction between these two factors was
significantly different between NBD and vehicle treated groups.
Stimulation frequency was 4 Hz, at 37°C. * indicates a difference of
P < 0.05 between the two groups.
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Page 6 of 10Figure 6 Histological analyses of tissue damage indicators in representative serial sections of hearts from vehicle and NBD peptide
treated dko mice show similar pathology in both treatment groups. A. Hematoxylin and eosin (H&E) staining shows the presence of
fibrotic scars in dko hearts from vehicle and NBD-treated groups. B. Immunostaining for collagen I shows localization of collagen in fibrotic
regions. C. ER-TR7 immunostaining demonstrates fibroblasts are a major cellular infiltrate in regions of fibrosis. D. CD-45 immunostaining shows
that immune cells are not detected in fibrotic scars at the time-point of analysis. Scale bar equals 50 μm.
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showed that a peptide referred to as NBD which blunts
NF-B signaling, can restore cardiac contractile dysfunc-
tion in a mouse model of DMD. Not only did NBD
treatment increase contractile force substantially, it also
improved key governing mechanisms of contractile force
that are typically impaired in patients with heart failure
including force-frequency behavior and the response to
b-adrenergic stimulation[11,12,25].
For this proof-of-principle study, we did not include
additional models of muscular dystrophy or wild-type
mice. However, we can compare the contractile
response to our previous study[10] in which we used
healthy, wild-type mice as well as mdx (dystrophin defi-
cient) mice. Mdx mice are the genotypic, often-used
model of DMD with a much milder phenotype (less
contractile dysfunction) compared to dko mice. In our
current study, we used the small right ventricular papil-
lary muscle with an average muscle dimension of 266 ±
8 μmw i d e ,1 7 7±5μm thick in the center, and 1.04 ±
0.08 mm long. In our previous work[10], we used right
ventricular thin trabeculae from mdx,d k om i c e ,a n d
C57Bl/10 isogenic controls. The trabeculae used pre-
viously were slightly narrower (average width of 220
μm) and longer (average 1.5 mm). However, although
trabeculae are very well suited for assessment of con-
tractile function in general[26], their frequency of
occurrence is less predictable than the always-present
papillary muscles. In this study we chose to use papillary
muscles based on their frequency of occurrence (i.e.
increased success rate of experiment) together with the
short life-span of the dko mouse (~10-12 weeks). When
we normalize both studies to the dko mouse contractile
force, shown in Figure 7, we can deduce that the
improvement in contractile force is very substantial. In
fact, forces produced during baseline conditions in NBD
treated dko mice are relatively similar to those obtained
in C57 wild-type mice, and higher than those obtained
in untreated mdx mice. In addition, the responses to
increased stimulation frequency as well as to b-adrener-
gic stimulation in NBD treated dko mice closely mimic
those observed in healthy C57 wild-type mice[10].
The increased contractile strength was likely not a
direct effect of altered histology of the myocardium. We
observed no significant reduction in fibrosis in the dko
myocardium upon treatment with NBD. However, we
cannot at this point exclude that local improvements in
the histology of papillary muscles may play a role. Most
of the area of the right ventricle and septum where the
muscles were excised is unsuitable for histological analy-
sis due to the dissection. The muscles used for physiolo-
gical force measurements, after experimentation, are
also not suitable for histological analysis and subsequent
correlative analysis. Thus, we cannot show a potential
histological change in the preparations where function
was actually assessed. However, given the widespread
fibrosis that was still clearly present in the remaining
ventricular tissue after NBD treatment, a local improve-
ment of histopathology being primarily responsible for
the improved function is quite unlikely. At present, and
well beyond the scope of this proof-of-principle study,
we can only speculate about the underlying molecular
events that ultimately result in an improvement of con-
tractile function.
The underlying cause of weakened contractile perfor-
mance of the end-stage heart failing myocardium is
often independent of the originating cause of heart fail-
ure in a patient or animal model. Impaired calcium
handling is a central finding in end-stage heart failure,
and this impaired calcium handling correlates with the
blunting, or even loss, of frequency-dependent activa-
tion. In human heart failure, the normal positive force
frequency response is typically severely blunted, or even
becomes negative, and is a hallmark of the phenotypic
dysfunction[11,24,25]. In normal, healthy mice, when
frequency of contraction is increased, the force develop-
ment of the muscle is generally slightly increased[27] or
at least does not show a major decrease, while relaxation
is always faster[19]. However, in mice with cardiac dys-
function, such as the dko mouse used in this study, the
force-frequency relationship is clearly negative[10]. We
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Figure 7 Indirect comparison of functional improvement of
dko myocardium by NBD treatment shows that the functional
improvement in baseline cardiac contractile force (4 Hz,
optimal length, 37°C) resulted in forces that are comparable
with age-matched C57BL/10 wild type muscles, and relatively
exceed those assessed in mdx myocardium under identical
experimental conditions. Data from this study and from Ref. [10].
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Page 8 of 10show that NBD treatment not only increases contractile
strength of dko myocardium, but it also significantly
improved the force-frequency relationship. This
response was no longer largely negative, and even
reverted to positive at the lower end of the frequency
range, resembling the frequency-dependent behavior
typically found in healthy mice. The restoration of a
normal force-frequency response is thus indirect evi-
dence that calcium handling improvement may be the
major underlying factor in the functional improvement
of dko myocardium after NBD treatment.
NF-B and calcium ions are both multifaceted signal-
ing molecules and interactions between calcium ion
concentration and NF-B have been documented. For
instance, in smooth muscle, NF-B is negatively
impacted by calcium channels[28], and thus inhibition
by NBD could potentially upregulate these calcium
channels, improving function by facilitating calcium
influx. Also, inhibition of NF-B has been shown to be
able to alleviate sarcoplasmic reticulum stress, and inter-
act with levels of the sarcoplasmic/endoplasmic reticu-
lum calcium ATPase (SERCA), which is responsible for
the uptake of calcium ions from the cytoplasm[29]. NF-
B in skeletal muscle has been shown to modulate
expression of nitric oxide synthase (NOS) isoforms[30],
which play an important role in maintaining cardiovas-
cular homeostasis mainly via calcium handling. Lastly, a
recent report by Panama and colleagues [31] showed
that NF-B downregulates the transient outward potas-
sium current in the heart, further providing evidence for
a role of NF-B regulated processes in excitation-con-
traction (EC)-coupling. Therefore, although we have no
direct conclusive evidence at this stage, NBD may
improve contractile function in dko myocardium via
improvement in EC-coupling/calcium handling, rather
than via a prevention of cardiac histologically-detectable
damage. Dystrophic skeletal muscle function can be
improved by low levels of dystrophin in absence of his-
topathological improvement[32]. Therefore, a similar
improvement of function of non-fibrotic dystrophic
myocardium may account for the results of our study.
Further targeted studies are required to elucidate possi-
ble mechanisms and could include electrophysiological
and heamodynamic assessments[33,34], as well as intra-
cellular calcium handling[19]. Any therapeutic strategy
involving NBD may require a combinatorial approach
with a factor that would prevent cardiac damage
In addition to reduced contractility and a negative
force-frequency response, it is well known that both in
patients with heart failure, as well as in many animal
models of cardiac dysfunction, the physiological
response to b-adrenergic stimulation is severely blunted
[12]. In untreated dko myocardium, this blunted b-adre-
nergic response is typically observed, and is severe[10],
and in the present study we found that NBD treatment
significantly improves this response. The main underly-
ing molecular level events that lead to increased con-
tractility after b-adrenergic stimulation may again be
found in the enhancement of the intracellular calcium
transient. Thus, the same mechanism responsible for the
improved force-frequency response could be the main
factor for improvement of this b-response.
Conclusions
In this study we show that inhibition of NF-Bu s i n g
the small peptide inhibitor NBD improves contractile
force, improves the force-frequency relationship, and
restores the response to b-adrenergic stimulation in the
well-established murine model for cardiac dysfunction
a s s o c i a t e dw i t hD M D .S i n c ew eh a v ed e m o n s t r a t e da
therapeutic effect of NBD on both skeletal[6] and car-
diac muscle (this study), NBD peptide treatment may be
a realistic treatment option for this debilitating disease.
Moreover, because the dko mouse model recapitulates
many of the contractile phenotypes found in the major-
ity of patients with end-stage failure stemming from a
variety of etiologies, NBD treatment may be useful
beyond the field of muscular dystrophy.
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